Author + information
- Received September 17, 2018
- Revision received January 29, 2019
- Accepted February 2, 2019
- Published online June 24, 2019.
- Ambra Albertario, PhD,
- Megan M. Swim, PhD,
- Eltayeb Mohamed Ahmed, MCh,
- Dominga Iacobazzi, PhD,
- Michael Yeong, MBBS,
- Paolo Madeddu, MD,
- Mohamed T. Ghorbel, PhD∗ ( and )
- Massimo Caputo, MD∗∗ ()
- ↵∗Address for correspondence:
Prof. Massimo Caputo, and Dr Mohamed Ghorbel, University of Bristol, Bristol Heart Institute, Research Level 7, BRI, Upper Maudlin Street, Bristol BS2 8HW, United Kingdom
• T-MSCs were isolated from the thymus gland of new born pigs, expanded, characterized and seeded onto a commercially available scaffold.
• The seeded-grafts were cultured within a bioreactor and then used to reconstruct the RVOT of a growing swine model.
• Pigs were followed up for 4.5 months; then scanned with a cardiac magnetic resonance and terminated to harvest the implants.
• By comparing the outcome of the seeded-grafts to the unseeded-ones used as control, we observed a reduced fibrosis and an improved RVOT strain, cardiac remodeling and endothelialization.
Graft cellularization holds great promise in overcoming the limitations associated with prosthetic materials currently used in corrective cardiac surgery. In this study, the authors evaluated the advantages of graft cellularization for right ventricular outflow tract reconstruction in a novel porcine model. After 4.5 months from implantation, improved myocardial strain, better endothelialization and cardiomyocyte incorporation, and reduced fibrosis were observed in the cellularized grafts compared with the acellular grafts. To the authors’ knowledge, this is the first demonstration of successful right ventricular outflow tract correction using bioengineered grafts in a large animal model.
- congenital heart disease
- right ventricular outflow swine model
- tissue engineering
- tract stem cells
↵∗ Drs. Ghorbel and Caputo contributed equally to this paper and are joint senior authors.
This study was supported by grants from the Sir Jules Thorn Charitable Trust (Drs. Caputo and Madeddu), the Enid Linder Foundation (Drs. Caputo and Ghorbel), the British Heart Foundation (Dr. Caputo), the National Institute for Health Research Bristol Biomedical Research Unit in Cardiovascular Medicine (Dr. Caputo), and the Medical Research Council (Drs. Madeddu, Caputo, and Ghorbel). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and U.S. Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received September 17, 2018.
- Revision received January 29, 2019.
- Accepted February 2, 2019.
- 2019 The Authors